June 15, 2017 / 11:31 PM / a month ago

BRIEF-Antisense Therapeutics updates on positive effects of a phase II study

1 Min Read

June 16 (Reuters) - Antisense Therapeutics Ltd

* Phase II study has shown atl1102 significantly reduces number of active MS lesions that convert to "black holes" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below